Molecular fields in drug discovery: getting old or reaching maturity?

Drug Discovery Today

Volumn 15, Issue 1-2, 2010, Pages 23-32

  Cross, Simon ^a   Cruciani, Gabriele ^b  

^a Molecular Discovery Limited   (United Kingdom)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPUTER ANALYSIS; COMPUTER MODEL; COMPUTER PROGRAM; CONFORMATIONAL TRANSITION; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DOCKING; MOLECULAR INTERACTION; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; VIRTUAL REALITY;

COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73749087803     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.12.006     Document Type: Review

References (67)

1. Kapetanovic I.M. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem. Biol. Int. 171 (2008) 165-176
2. Clark D.E. What has computer-aided molecular design ever done for drug discovery?. Expert Opin. Drug Discov. 1 (2006) 103-110
3. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997) 3
4. Clark D.E. What has virtual screening ever done for drug discovery?. Expert Opin. Drug Discov. 3 (2008) 841-851
5. Lewis R.A. A general method for exploiting QSAR models in lead optimization. J. Med. Chem. 48 (2005) 1638-1648
6. Von Itzstein M., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
7. Cross S.S.J. Improved FlexX docking using FlexS-determined base fragment placement. J. Chem. Inf. Model. 45 (2005) 993-1001
8. Evers A., et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 47 (2004) 5381-5392
9. Cruciani G., et al. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 11 (2000) S29-S39
10. Cruciani G., et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 48 (2005) 6970-6979
11. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857
12. Cramer R.D., et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
13. a prediction method using grid molecular interaction fields. J. Chem. Inf. Model. 47 (2007) 2172-2181
14. ACDpKa, V. 8. 03 (2007), Advanced Chemistry Development
15. Milletti, F. et al. Tautomer enumeration and stability prediction for virtual screening on large chemical databases. J. Chem. Inf. Model. Jan 6, 2009, doi:10.1021/ci800340j.
16. Wild D.J., et al. Similarity searching in files of three-dimensional chemical structures. Alignment of molecular electrostatic potential fields with a genetic algorithm. J. Chem. Inf. Comput. Sci. 36 (1996) 159-167
17. Tervo A.J., et al. Optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications. J. Med. Chem. 48 (2005) 4076-4086
18. Mestres J., et al. MIMIC: a molecular-field matching program, exploiting applicability of molecular similarity approaches. J. Comput. Chem. 18 (1996) 934-954
19. Fradera X., et al. Similarity-driven flexible ligand docking. Proteins: Struct. Funct. Genet. 40 (2000) 623-636
20. Cramer R.D., et al. Bioisosterism as a molecular diversity descriptor: steric fields of single topomeric conformers. J. Med. Chem. 39 (1996) 3060-3069
21. Cramer R.D., et al. Prospective identification of biologically active structures by topomer shape similarity searching. J. Med. Chem. 42 (1999) 3919-3933
22. Andrews K.M., et al. Toward general methods of targeted library design: topomer shape similarity searching with diverse structures as queries. J. Med. Chem. 43 (2000) 1723-1740
23. Cramer R.D., et al. dbtop: topomer similarity searching of conventional structure databases. J. Mol. Graph. Model. 20 (2002) 447-462
24. Cramer R.D., et al. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. J. Med. Chem. 47 (2004) 6777-6791
25. Jilek R.J., et al. Topomers: a validated protocol for their self-consistent generation. J. Chem. Inf. Comput. Sci. 44 (2004) 1221-1227
26. 20 synthetically accessible structures. J. Comput. Aid. Mol. Des. 21 (2007) 341-350
27. Vinter J.G. Extended electron distributions applied to the molecular mechanics of intermolecular interactions. J. Comput. Aid. Mol. Des. 8 (1994) 653-668
28. Vinter J.G. Extended electron distributions applied to the molecular mechanics of intermolecular interactions. II. Organic complexes. J. Comput. Aid. Mol. Des. 10 (1996) 417-426
29. Cheeseright T., et al. Molecular field extrema as descriptors of biological activity: definition and validation. J. Chem. Inf. Model. 46 (2006) 665-676
30. Huang N., et al. Benchmarking sets for molecular docking. J. Med. Chem. 49 (2006) 6789-6801
31. Cheeseright T., et al. FieldScreen: virtual screening using molecular fields. Application to the DUD data set. J. Chem. Inf. Model. 48 (2008) 2108-2117
32. Low C.M.R., et al. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists. J. Med. Chem. 48 (2005) 6790-6802
33. Cheeseright T., et al. Molecular field technology applied to virtual screening and finding the bioactive conformation. Expert Opin. Drug Discov. 2 (2007) 131-144
34. Baroni M., et al. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): theory and application. J. Chem. Inf. Model. 47 (2007) 279-294
35. Carosati E., et al. Calcium channel antagonists discovered by a multidisciplinary approach. J. Med. Chem. 49 (2006) 5206-5216
36. Bergmann R., et al. SHOP: scaffold HOPping by GRID-based similarity searches. J. Med. Chem. 50 (2007) 2708-2717
37. Cruciani G., et al. A search for specificity in DNA-drug interactions. J. Mol. Graph. 12 (1994) 116-129
38. Pastor M., et al. A novel strategy for improving ligand selectivity in receptor-based drug design. J. Med. Chem. 38 (1995) 4637-4647
39. Filipponi E., et al. Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands. J. Comput. Aid. Mol. Des. 14 (2000) 277-291
40. Braiuca P., et al. A homology model of penicillin acylase from Alcaligenes faecalis and in silico evaluation of its selectivity. ChemBioChem 4 (2003) 615-622
41. Braiuca P., et al. An innovative application of the "flexible" GRID/PCA computational method: study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant. Biotechnol. Prog. 20 (2004) 1025-1031
42. Kastenholz M.A., et al. GRID/CPCA: a new computational tool to design selective ligands. J. Med. Chem. 43 (2000) 3033-3044
43. Ridderström M., et al. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA. J. Med. Chem. 44 (2001) 4072-4081
44. Naumann T., et al. Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. J. Med. Chem. 45 (2002) 2366-2378
45. Terp G.E., et al. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J. Med. Chem. 45 (2002) 2675-2684
46. Ji H., et al. Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors. J. Med. Chem. 46 (2003) 5700-5711
47. Pirard B. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. J. Comput. Aid. Mol. Des. 17 (2003) 785-796
48. Kurz M., et al. Insights into the bile acid transportation system: The human ileal lipid-binding protein-cholyltaurine complex and its comparison with homologous structures. Proteins: Struct. Funct. Genet. 50 (2003) 312-328
49. Myshkin E., et al. Chemometrical classification of ephrin ligands and Eph kinases using GRID/CPCA approach. J. Chem. Inf. Comput. Sci. 43 (2003) 1004-1010
50. Fox T. Protein selectivity studies using GRID-MIFs. In: Cruciani G. (Ed). Molecular Interaction Fields (2006), Wiley 45-82
51. Klebe G., et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37 (1994) 4130-4146
52. Kellogg G.E., et al. HINT: a new method of empirical hydrophobic field calculation for CoMFA. J. Comput. Aid. Mol. Des. 5 (1991) 545-552
53. Goodford P. Multivariate characterization of molecules for QSAR analysis. J. Chemom. 10 (1996) 107-117
54. Doweyko A.M. The hypothetical active site lattice - in vitro and in vivo explorations using a three-dimensional QSAR technique. J. Math. Chem. 7 (1991) 273-285
55. Jain A.N., et al. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. J. Med. Chem. 37 (1994) 2315-2327
56. Gohlke H., et al. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J. Med. Chem. 45 (2002) 4153-4170
57. Pastor M., et al. GRid-INdependent Descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J. Med. Chem. 43 (2000) 3233-3243
58. Fontaine F., et al. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-Independent descriptors. J. Med. Chem. 48 (2005) 2687-2694
59. Filipponi E., et al. QSAR study and VolSurf characterization of anti-HIV quinolone library. J. Comput. Aid. Mol. Des. 15 (2001) 203-217
60. Cramer R.D. Topomer CoMFA: a design methodology for rapid lead optimization. J. Med. Chem. 46 (2003) 374-388
61. Low C.M.R., et al. Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points. J. Med. Chem. 51 (2008) 565-573
62. Crivori P., et al. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 43 (2000) 2204-2216
63. Mannnhold R., et al. Use of MIF-based VolSurf descriptors in physicochemical and pharmacokinetic studies. In: Cruciani G. (Ed). Molecular Interaction Fields (2006), Wiley 173-196
64. Cianchetta G., et al. Molecular interaction fields in ADME and safety. In: Cruciani G. (Ed). Molecular Interaction Fields (2006), Wiley 45-82
65. Zamora I., et al. Prediction of oral drug permeability. In: Holdje H.D., and Sippl W. (Eds). Rational Approaches to Drug Design (2001), Prous Science 271-280
66. Gebauer S., et al. Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter PEPT1. J. Med. Chem. 46 (2003) 5725-5734
67. Ahlström M.M., et al. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. J. Med. Chem. 50 (2007) 4444-4452